Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (39)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hakama, M.
Right arrow Articles by Teppo, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hakama, M.
Right arrow Articles by Teppo, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Vol. 137, No. 2: 166-170
Copyright © 1993 by The Johns Hopkins University School of Hygiene and Public Health

research-article

Serum Antibodies and Subsequent Cervical Neoplasms: A Prospective Study with 12 Years of Follow-up

Matti Hakama1,2,, Matti Lehtinen1, Paul Knekt3, Arpo Aromaa3, Pauli Leinikki1, Ari Miettinen1, Jorma Paavonen1, Richard Peto4 and Lyly Teppo2

1Faculty of Medicine, University of Tampere Tampere, Finland
2Finnish Cancer Registry Helsinki, Finland
3Social Insurance Institution Helsinki, Finland
4Imperial Cancer Research Fund, Cancer Studies Unit, Radcliffe Infimary Oxford, England

Reprint requests to Dr. Matti Hakama, Department of Public Health, Faculty of Medicine, University of Tampere, P O. Box 607, SF-33101 Tampere, Finland

Approximately 40,000 blood samples drawn in 1968–1972 by the Social Insurance Institution's mobile clinic in Finland have been stored. Linking cancer incidence data obtained from the Finnish Cancer Registry with this material yielded 32 cases of cervical cancer diagnosed after drawing of the blood sample. These 32 individuals and 64 matched controls were analyzed for serum antibodies indicative of past infection with Chlamydia trachomatis, Neisseria gonorrhoeae, cytomegalovirus, Epstein-Barr virus, and herpes simplex virus type 2. After adjustment for smoking and other sexually transmitted diseases, antibodies to C. trachomatis showed the strongest association with cervical cancer (odds ratio = 5.0 (95% confidence interval 1.6–15.7)), but the numbers were too small for drawing conclusions as to the sexually transmitted diseases with which cervical cancer is most specifically associated. Am J Epidemiol 1993;137: 166–70.

cervix neoplasms; Chlamydia trachomatis; cytomegaloviruses; Epstein-Barr virus; follow-up studies; herpes simplex; Neisseria gonorrhoeae; risk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Sex. Transm. Infect.Home page
Y-P Yin, R W Peeling, X-S Chen, K-L Gong, H Zhou, W-M Gu, H-P Zheng, Z-S Wang, G Yong, W-L Cao, et al.
Clinic-based evaluation of Clearview Chlamydia MF for detection of Chlamydia trachomatis in vaginal and cervical specimens from women at high risk in China
Sex Transm Inf, December 1, 2006; 82(suppl_5): v33 - v37.
[Abstract] [Full Text] [PDF]

Home page
 Sex. Transm. Infect.Home page
X-S Chen, Y-P Yin, D Mabey, R W Peeling, H Zhou, W-H Jiang, W-H Wei, G Yong, M-Q Shi, Q Chen, et al.
Prevalence of Chlamydia trachomatis infections among women from different settings in China: implications for STD surveillance.
Sex Transm Inf, August 1, 2006; 82(4): 283 - 284.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. Anttila, L. Tenkanen, S. Lumme, M. Leinonen, R. E. Gislefoss, G. Hallmans, S. Thoresen, T. Hakulinen, T. Luostarinen, P. Stattin, et al.
Chlamydial Antibodies and Risk of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 385 - 389.
[Abstract] [Full Text] [PDF]

Home page
 Sex. Transm. Infect.Home page
K A Fenton and C M Lowndes
Recent trends in the epidemiology of sexually transmitted infections in the European Union
Sex Transm Inf, August 1, 2004; 80(4): 255 - 263.
[Abstract] [Full Text] [PDF]

Home page
 Sex. Transm. Infect.Home page
M Molano, E Weiderpass, H Posso, S A Morre, M Ronderos, S Franceschi, A Arslan, C J L M Meijer, N Munoz, and A J C van den Brule
Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia
Sex Transm Inf, December 1, 2003; 79(6): 474 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Sex. Transm. Infect.Home page
J. Paavonen
Chlamydia trachomatis and cancer
Sex Transm Inf, June 1, 2001; 77(3): 154 - 156.
[Full Text] [PDF]

Home page
 Sex. Transm. Infect.Home page
N Reesink-Peters, J M Ossewaarde, A G J Van Der Zee, W G V Quint, M P M Burger, and A H Adriaanse
No association of anti-Chlamydia trachomatis antibodies and severity of cervical neoplasia
Sex Transm Inf, April 1, 2001; 77(2): 101 - 102.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
L Kjellberg, Z Wang, F Wiklund, K Edlund, T Angstrom, P Lenner, I Sjoberg, G Hallmans, K. Wallin, M Sapp, et al.
Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study
J. Gen. Virol., February 1, 1999; 80(2): 391 - 398.
[Abstract]

Home page
 BMJHome page
M. Lehtinen, J. Dillner, P. Knekt, T. Luostarinen, A. Aromaa, R. Kirnbauer, P. Koskela, J. Paavonen, R. Peto, J. T Schiller, et al.
Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study
BMJ, March 2, 1996; 312(7030): 537 - 539.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.